- $2.20bn
- $1.99bn
- $226.47m
- 66
- 17
- 74
- 51
2020 January 31st | 2021 January 31st | 2022 January 31st | 2023 January 31st | 2024 January 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 229 | 223 | 332 | 338 | 226 |
Cost of Revenue | |||||
Gross Profit | 133 | 136 | 208 | 209 | 137 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 278 | 284 | 361 | 412 | 381 |
Operating Profit | -49.6 | -61.2 | -29.6 | -74.3 | -155 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -41.6 | -57.3 | -28.6 | -70.9 | -149 |
Provision for Income Taxes | |||||
Net Income After Taxes | -44.8 | -59.8 | -26.4 | -65.4 | -169 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -44.8 | -59.8 | -26.4 | -65.4 | -169 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -44.8 | -59.8 | -26.4 | -65.4 | -169 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.35 | -1.72 | -0.655 | -1.65 | -4.25 |